Hansoh Pharmaceutical's Dual-Faced Transformation: From Generic Roots to Innovation Powerhouse Amid Governance Scrutiny

Introduction:Hansoh Pharma raised the share of innovative drug revenue from less than 20% to over 85% in five years, achieving the highest earnings quality with virtually no leverage, making it one of the most aggressive examples of transformation among traditional pharmaceutical companies.

Author | Ruiyan Consumer

Edited by Emma

Recently, Hansoh Pharma (3692.HK) has become the focus of attention in the Hong Kong-listed pharmaceutical sector due to its continuous stream of positive news.

Goldman Sachs released a report stating that Ruikang Lifu Tuo Ta Dan Keng (HS-20093), with the international nonproprietary name Risvutatug Rezetecan (abbreviated as Ris-Rez), is an antibody-drug conjugate (ADC) targeting B7-H3, and has achieved positive overall survival (OS) data in its Phase III study for small cell lung cancer. Goldman Sachs maintained a "Buy" rating with a target price of HK$52.7, noting that market focus will shift from "whether it is effective" to "first-line expansion and breadth of indications."

On September 16, the company voluntarily announced that its injectable drug HS-20197, a novel and independent Class 1 new drug, received approval for clinical trials on September 11, 2026. The planned Phase I clinical study will focus on advanced solid tumors to evaluate its safety and tolerability.

These data are indeed encouraging. However, viewed over a longer timeline, the story of Hansoh Pharma extends far beyond the clinical readouts of a single ADC. It is a pharmaceutical company that has emerged from the red ocean of generic drugs, successfully executing an innovation-driven transformation with remarkable precision. At the same time, it remains a company frequently associated with compliance controversies, questions regarding related-party transactions, and concerns about its reliance on a single product.

The story of Hansoh Pharma began in 1995. At that time, the thenLianyungangSun Piaoyang, the head of the pharmaceutical factory, faced risks associated with corporate restructuring. To secure a "fallback option" for himself, he co-founded Hansoh Pharmaceutical (the predecessor of Hansoh Pharma) in Lianyungang with his partner Cen Junda. The company was initially positioned more as a risk-hedging "alternative vehicle," and thus long bore the label from outside observersHengrui Medicine“Affiliated Enterprise” label. The company’s actual operations are managed by Zhong Huijuan, wife of Sun Piaoyang, while their daughter, Sun Yuan, serves as Executive Director.

Hansoh Pharma’s current most profitable blockbuster product is Aumetinib Mesylate Tablets (brand name: Ameile), primarily used for the treatment of lung cancer, specifically targeting patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

Based on the 2025 sales data across all terminals, Aumolertinib achieved sales revenue of RMB 5.53 billion, ranking first in sales of innovative drugs in the Chinese market in 2025 and becoming the best-selling domestically produced innovative drug of that year-1. In the first half of 2026, the revenue from anti-tumor products represented by Ameile was approximately RMB 5.473 billion, accounting for 65.9% of the company's total revenue, remaining the core engine driving performance growth.

01

Transformation Quality: Highest Purity, Insufficient Thickness

Hansoh Pharma’s transformation speed is virtually unmatched among traditional pharmaceutical companies. The proportion of revenue from innovative drugs surged from 18% in 2020 to 82.7% in 2025, further reaching 85.4% in the first half of 2026. The selling expense ratio was compressed from 38% in 2019 to 27% in 2025, while the gross profit margin remained stable at around 90%, and the net profit margin reached as high as 36.97%. In 2025, the company reported full-year revenue of RMB 15.028 billion, net profit of RMB 5.555 billion, and operating cash flow of RMB 6.738 billion, which exceeded net profit. Capital expenditures amounted to only RMB 489 million, resulting in free cash flow exceeding RMB 6 billion.

These figures outline an innovative pharmaceutical company with high-quality earnings, robust cash flow, and excellent cost control. In peer comparisons, Hansoh Pharma ranks first in both net profit margin and gross profit margin, significantly outperforming Hengrui Medicine, China Biopharmaceutical Holdings, and CSPC Pharmaceutical Group. JPMorgan has even explicitly stated a preference for Hansoh over Hengrui, citing “more attractive risk-reward at current levels.”

However, the flip side of leading in “purity” is insufficient “depth.” Hansoh Pharma’s revenue scale is approximately half that of Hengrui, with an R&D investment of RMB 3.36 billion, amounting to only 38.5% of Hengrui’s.BeiGene23%. Approximately 7 innovative products have been approved, compared to over 30 for Hengrui. More critically, a single product, almonertinib, accounts for nearly half of the revenue from innovative drugs, making its reliance on this single asset the most pronounced among comparable companies. Should almonertinib face patent challenges, competitive pressure, or price reductions in national medical insurance negotiations, its performance volatility would be significantly higher than that of Hengrui or China Biopharmaceuticals, which have more diversified pipelines.

02

Financial Margins: New Changes Under Low Leverage

In 2024 and 2025, Hansoh Pharma’s interest-bearing debt was nearly zero, with the ratio of interest-bearing debt to total invested capital standing at just 0.14% and 0.11%, respectively. The debt-to-asset ratio declined steadily from 70.67% in 2018 to 9.41% in 2024, and reached only 11.37% in 2025. Shareholders’ equity increased from RMB 20 billion in 2021 to RMB 35.4 billion in 2025. This represents an almost impeccable balance sheet.

However, the 2026 interim report broke this trend. The asset-liability ratio rebounded to 18.96%, and the ratio of interest-bearing debt to total invested capital rose to 9.76%. Based on an estimated equity attributable to shareholders-to-interest-bearing debt ratio of 9.25x, new interest-bearing debt amounted to approximately RMB 4 billion. The current ratio decreased from 8.09 in 2025 to 4.88, while the conservative quick ratio declined from 1.55 to 0.95, slightly below 1. The ratio of cash and cash equivalents to current liabilities dropped from 0.78 to 0.55.

Meanwhile, the net profit margin surged to 51.28% in the first half of 2026, significantly higher than the full-year figure of 36.97% in 2025. Operating profit amounted to RMB 3.706 billion, while pre-tax profit reached RMB 5.009 billion, resulting in a difference of approximately RMB 1.3 billion, suggesting that non-operating or licensing income made a substantial contribution to the current period’s profits.

Viewed together, these two developments point to a critical issue requiring close monitoring: How was the newly added RMB 4 billion in interest-bearing debt utilized? If the funds were directed toward R&D advancement, business development (BD) transactions, or capacity expansion, and if licensing revenues demonstrate sustainability, then the current financial shifts are strategic and manageable. However, if the high net profit margin is primarily driven by one-time upfront licensing payments while debt levels rise concurrently, both profit growth rates and debt-servicing metrics in the second half of 2026 could face significant pressure.

03

Controversial Background: Old Issues of Compliance and Governance

Controversies surrounding Hansoh Pharma are nothing new. In July 2024, its subsidiary, Jiangsu Hengte Pharmaceutical, was fined and had illicit gains confiscated totaling RMB 25.54 million for unfair competition practices. Disclosed details included payments of over RMB 860,000 in service fees to 46 physicians and systematic fraud in academic activities—such as personnel from the same department wearing heavy clothing one day and short sleeves the next, and two doctors delivering identical presentations to each other. In 2021, an inspection by the Ministry of Finance found that Hansoh Pharmaceutical had fabricated expenses amounting to RMB 150 million, including RMB 129 million in invoices for which no records could be found and RMB 16 million in fictitious consulting and review fees.

These incidents are not isolated. The company’s sales and distribution expenses have exceeded RMB 3 billion for seven consecutive years, totaling over RMB 14.3 billion from 2021 to 2024, which is significantly higher than the R&D expense ratio during the same period. The correlation between high sales expenses and compliance risks has long been a concern in the market.

Data Source: Company Announcements

Another issue that continues to be discussed is related-party transactions. The actual controllers of Hansoh Pharma and Hengrui Medicine are a married couple, with over 60% overlap in their product portfolios and personnel cross-over within their sales teams. In December 2025, Hengrui licensed SHR6508 to Hansoh for an upfront payment of RMB 30 million, milestone payments totaling up to RMB 190 million, plus royalties of up to 9% on sales. Given the familial relationship between the two companies’ actual controllers, this transaction was not conducted entirely as an arm’s-length deal between independent third parties. Issues concerning the fairness of pricing and the protection of minority shareholders’ interests warrant continued attention.

Goldman Sachs’ Ris-Rez report has given the market a reason for excitement. However, competition in the ADC space is intensifying, and uncertain variables include GSK’s global R&D progress, clinical readouts from competitors, and the impact of geopolitical factors on overseas licensing deals.

The true test for Hansoh Pharma lies in whether it can develop a second and third billion-dollar product following almonertinib, whether its increased debt can be translated into verifiable R&D outputs, and whether compliance and internal controls can genuinely improve under its high sales expense model. There are no simple answers to these questions, yet they will determine whether Hansoh Pharma becomes a exemplar of “small but specialized” transformation or remains a phase-specific story driven by a single product.